Publication date: Nov 26, 2019
The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease.
AMP PD is a public-private partnership between the National Institutes of Health, the U. S. Food and Drug Administration, with industry (Celgene, GSK, Pfizer, Sanofi and Verily) and non-profit (The Michael J. Fox Foundation for Parkinson’s Research) organizations and managed through the Foundation of the National Institutes of Health (FNIH).
The AMP PD Knowledge Portal contains data from cerebrospinal fluid, RNA, plasma and DNA samples previously collected through programs including The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and National Institute of Neurological Disorders and Stroke (NINDS) BioFIND Study, the Harvard Biomarkers Study of Brigham and Women’s Hospital and Massachusetts General Hospital, the NINDS Parkinson’s Disease Biomarkers Program, and MJFF’s Parkinson’s Progression Markers Initiative.
-The AMP model has provided a unique platform for bringing together diverse patient cohorts, advances in technology and scientific expertise to study Parkinson’s disease on a scale that has not been attempted before,” said David Wholley, Senior Vice President, Research Partnerships, FNIH.
-With the AMP PD Knowledge Portal, we are helping the scientific community worldwide to fast-track discoveries that we hope will ultimately help Parkinson’s disease patients and their families. “
About AMP PD: The Parkinson’s disease initiative is a part of the Accelerating Medicines Partnership, a joint venture between the National Institutes of Health, the U. S. Food and Drug Administration, six industry partners and one non-profit organization, managed by the Foundation for the NIH, to identify and validate promising biomarkers for Parkinson’s disease.
- Data portal offers de-identified info on patients with Parkinson’s
- Potential two-step proteomic signature for Parkinson’s disease: Pilot analysis in the Harvard Biomarkers Study.
- Researchers uncover new molecular drivers of Parkinson’s disease